

## Putting NICE guidance into practice

### **Resource impact report: Abatacept, adalimumab, etanercept and tocilizumab for treating juvenile idiopathic arthritis (TA373)**

Published: December 2015

The technologies are commissioned by NHS England for paediatric patients and clinical commissioning groups for adults.

The full recommendations are available in NICE's guidance on [abatacept, adalimumab, etanercept and tocilizumab for treating juvenile idiopathic arthritis](#).

The companies that hold the marketing authorisations for abatacept and tocilizumab have each agreed a patient access scheme with the Department of Health. There is no patient access scheme for adalimumab and etanercept.

Both of these schemes provide a simple discount to the list price of each technology (abatacept or tocilizumab), with the discount applied at the point of purchase or invoice. The level of these discounts is commercial in confidence. It is the responsibility of each company to communicate details of the discount to the relevant NHS organisations.

Any enquiries from NHS organisations about the patient access scheme for tocilizumab should be directed to Roche Customer Care (0800 731 5711). Any enquiries from NHS organisations about the patient access scheme for abatacept should be directed to BMS Customer Services (Chester), phone number 01244 586250, or to the following e-mail address: [ukpasadmin@bms.com](mailto:ukpasadmin@bms.com)

It is unlikely that the guidance will result in a significant change in resource use in the NHS because it is considered that the recommendations are consistent with current clinical practice. Therefore no costing template has been produced.

© National Institute for Health and Care Excellence, 2015. All rights reserved. This material may be freely reproduced for educational and not-for-profit purposes. No reproduction by or for commercial organisations, or for commercial purposes, is allowed without the express written permission of NICE.